SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Elizabeth Barrett Browning

PatientElizabeth Barrett Browning
Date of birth1987-03-06
IdentifiersMRN HR-NI026-SYN; SSN (made up) 000-26-4157
Document date2026-04-20
AuthorClementine Haverford-Asante, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week review: cultures, airway clearance, bone density, grief therapy, and the opioid dose. [S]

History of Present Illness

Ms. Barrett Browning returns four weeks after the consultation. She does airway clearance every morning and evening and finds it tiring but worth it: her sputum is down from about four to two tablespoons a day, and she has seen no blood for two weeks. She has had four grief therapy sessions by video and says it is the first time she has spoken of her brother aloud; the first two sessions were very hard. She sleeps a little better. She had her DXA scan last week. She asks whether she could try a lower morphine dose, now that the cough is easing and she is sleeping a little better, but she does not want to stop it and is afraid of the restlessness she remembers when a dose was late. [S]

ElementDetail
Airway clearanceTwice daily; sputum down to two tablespoons a day; no blood for two weeks
Mycobacterial culturesNo growth at four weeks
Grief therapyFour sessions
Her requestA slow, small reduction in morphine

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; a little more energy
RespiratoryPositiveCough with two tablespoons of sputum a day; no blood
GastrointestinalPositiveStools every two days; no pain
PsychiatricPositiveGrief still heavy but more bearable; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued)5 mL (10 mg) twice daily, morning and bedtimeOral route2019-03-01 to 2026-04-19completedS
Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911As needed for suspected overdose; keep two devices at homeNasal route2026-03-16activeS
Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth dailyTwo tablets dailyOral route2026-03-16activeS
Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day)4.5 mL (9 mg) twice daily, morning and bedtimeOral route2026-04-20 to 2026-06-14completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height157cmS
2026-04-20Body weight42.4kgS
2026-04-20Body mass index (BMI) [Ratio]17.2kg/m2S
2026-04-20Systolic blood pressure104mm[Hg]S
2026-04-20Diastolic blood pressure66mm[Hg]S
2026-04-20Heart rate88/minS
2026-04-20Respiratory rate16/minS
2026-04-20Body temperature36.7CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20DXA Lumbar spine [Z-score] Bone density-1.4{Z-score}Above -2.0 is within the expected range for ageNormalS
2026-04-20DXA Femur [Z-score] Bone density-1.1{Z-score}Above -2.0 is within the expected range for ageNormalS
2026-04-20C reactive protein [Mass/volume] in Serum or Plasma4.1mg/L<=5 mg/LNormalS
2026-04-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]10{score}S

Physical Exam

Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]

SystemFinding
GeneralBrighter; weight 42.4 kg
RespiratoryFewer crackles at the left base; no wheeze
NeurologicalNot drowsy; pupils normal size
PsychiatricEngaged; tearful briefly when speaking of her brother; no suicidal ideation

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguishedresolvedconfirmed R05.3S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D).
Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputedactiveconfirmed J47.9S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed).
Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessmentactiveconfirmed Z79.891S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder.
Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideationactiveconfirmed F43.81S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health.
Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoorsactiveconfirmed E55.9S — Synthetic finding at intake; repleted by twelve weeks.
Underweight (BMI 16.8) with a small appetiteactiveconfirmed R63.6S — Synthetic finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryMycobacterial culture including nontuberculous mycobacteriaAt diagnosis (final at six to eight weeks), then yearly and with unexplained declineOrderedNo growth at four weeks; final at eight weeks
LaboratorySputum bacterial cultureAt each review and at every exacerbation, before antibioticsCompleted todayLight growth of Haemophilus influenzae; no Pseudomonas
LaboratoryC-reactive proteinWith symptoms or exacerbationCompleted today4.1 mg/L, from 8.4
Self-managementAirway clearance technique and exerciseEvery visitCompleted todayTwice daily with the oscillating PEP device; technique checked by the physiotherapist last week
Self-managementExacerbations: number in the past year, written plan, and rescue antibioticEvery visitCompleted todayNone since diagnosis; plan and antibiotic at home
Self-managementHemoptysis: amount, and when to seek emergency careEvery visitCompleted todayNo blood for two weeks
Medication safetyOpioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goalsEvery visit, and at least every three monthsCompleted todayNo sedation; cough and sleep improving; she chose a reduction
Medication safetyPrescription drug monitoring program checkWith every prescription, and at least every three monthsCompleted todayOne prescriber, one pharmacy
Medication safetyNaloxone at home, and no benzodiazepines or other sedativesEvery visitCompleted todayNaloxone at home; no sedatives
Medication safetyOpioid use disorder assessment (DSM-5-TR)At review and whenever there is concern; tolerance and withdrawal on prescribed use do not countCompleted todayNo criteria met apart from tolerance and withdrawal, which do not count on prescribed use
SurveyPHQ-9At least monthly during active treatment (CMID)Completed today10, from 12
ExaminationSuicide risk review and safety planEvery visitCompleted todayNo suicidal ideation; plan current
Self-managementGrief therapy attendance and responseWeekly for sixteen sessionsCompleted todayFour sessions attended
ImagingBone density (DXA)Once, for risk factors; repeat only if risk changesCompleted todaySpine Z -1.4, femoral neck Z -1.1: within the expected range
Laboratory25-hydroxyvitamin DTwelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID)Due15 ng/mL at intake; recheck at twelve weeks
ExaminationWeight and BMIEvery visitCompleted today42.4 kg, BMI 17.2, up 0.9 kg

Goal progress:

Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026)

Follow-up: Three-month review with the final mycobacterial cultures, vitamin D, PHQ-9 and GAD-7, and a check on the first dose step. Emergency care for more than a few teaspoons of blood. Next scheduled visit 2026-06-15: three-month review: final mycobacterial cultures, vitamin D, mood, safety, and the opioid dose. [S]